Bristol Myers Squibb (CELG-RI) Return on Sales (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Return on Sales of 0.0% for Q2 2026, little changed year-over-year from 0.0% in Q2 2025, and up 9.62% quarter-over-quarter from 0.0% in Q1 2026.
Bristol Myers Squibb (CELG-RI) Return on Sales (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Return on Sales for 18 consecutive years, with 0.0% the latest figure, recorded in Q2 2026.
- In Q2 2026, Return on Sales changed 0.0% year-over-year to 0.0%; the TTM figure through Jun 2026 stood at 0.0% (changed 0.0% YoY), while the FY2025 annual figure was 0.0%, changed 0.0% from the prior year.
- Return on Sales rose to 0.0% in Q2 2026 per CELG-RI's latest filing, from 0.0% in the prior quarter.
- Across five years, Return on Sales topped out at 0.0% in Q2 2026 and bottomed at 0.01% in Q1 2024.
- Historically, Return on Sales has averaged 0.0% across 5 years, with a median of 0.0% in 2023.
- Annual changes were most pronounced in 2024 — Return on Sales decreased 1 bps — and 2025, when it rose 1 bps.
- Bristol Myers Squibb's Return on Sales stood at 0.0% in 2022, then decreased by 14 bps to 0.0% in 2023, then plunged by 96 bps to 0.0% in 2024, then soared by 1311 bps to 0.0% in 2025, then soared by 194 bps to 0.0% in 2026.
- Business Quant data shows CELG-RI's Return on Sales at 0.0% in Q2 2026, 0.0% in Q1 2026, and 0.0% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 0.00% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 0.00% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 0.00% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 0.00% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 0.00% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 0.00% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -0.01% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 0.00% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 0.00% |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.00% |
| Mar 31, 2026 | 0.00% |
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | 0.00% |
| Jun 30, 2025 | 0.00% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2024 | 0.00% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | 0.00% |
| Mar 31, 2024 | -0.01% |
| Dec 31, 2023 | 0.00% |
| Sep 30, 2023 | 0.00% |
| Jun 30, 2023 | 0.00% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | 0.00% |
| Mar 31, 2022 | 0.00% |
| Dec 31, 2021 | 0.00% |
| Sep 30, 2021 | 0.00% |